Immunic, Inc.(IMUX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IMUX Immunic, Inc.

交易中 07-16 12:06:16 EDT

14.65

-0.45

-2.98%

最高15.16	最低14.51	成交量6.66万
今开14.89	昨收15.10	日振幅4.30%
总市值1.99亿	流通市值1.73亿	总股本1,360万
成交额98.92万	换手率0.56%	流通股本1,184万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IMUX","market":"US","secType":"STK","nameCN":"Immunic, Inc.","latestPrice":14.65,"timestamp":1784217949683,"preClose":15.1,"halted":0,"volume":66596,"delay":0,"changeRate":-0.029801324503311213,"floatShares":11842000,"shares":13600000,"eps":-7.656067,"marketStatus":"交易中","change":-0.45,"latestTime":"07-16 12:06:16 EDT","open":14.89,"high":15.16,"low":14.51,"amount":989152.9852440001,"amplitude":0.043046,"askPrice":14.64,"askSize":100,"bidPrice":14.54,"bidSize":24,"shortable":3,"etf":0,"ttmEps":-7.656067,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784232000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1397707200000,"exchange":"NASDAQ","adjPreClose":15.1,"preHourTrading":{"tag":"盘前","latestPrice":14.85,"preClose":15.1,"latestTime":"09:15 EDT","volume":36,"amount":537.268788,"timestamp":1784207731491,"change":-0.25,"changeRate":-0.016556,"amplitude":0.028503},"postHourTrading":{"tag":"盘后","latestPrice":14.8,"preClose":15.1,"latestTime":"19:37 EDT","volume":1148,"amount":17012.8646,"timestamp":1784158641650,"change":-0.3,"changeRate":-0.019868,"amplitude":0.019868},"volumeRatio":1.037064,"impliedVol":1.3834,"impliedVolPercentile":0.56},"requestUrl":"/m/hq/s/IMUX/tweets","defaultTab":"tweets","newsList":[{"id":"1130914337","title":"Immunic将在2026年CMSC年会上公布Vidofludimus钙二期CALLIPER试验新数据，进一步巩固其在进展型多发性硬化症中的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1130914337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130914337?lang=zh_cn&edition=full","pubTime":"2026-05-28 18:31","pubTimestamp":1779964275,"startTime":"0","endTime":"0","summary":"Immunic公司计划于2026年举行的CMSC（联合多发性硬化症中心）年度会议上，公布其候选药物Vidofludimus钙在二期CALLIPER临床试验中的补充数据。此次数据发布旨在进一步验证该药物在治疗进展型多发性硬化症方面的潜力，为后续临床开发提供关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196495681","title":"Immunic任命资深生物制药高管Michael W. Bonney为董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=1196495681","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196495681?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:31","pubTimestamp":1779186687,"startTime":"0","endTime":"0","summary":"Immunic公司宣布，任命在生物制药领域经验丰富的高管Michael W. Bonney为其董事会主席。这一重要人事变动旨在强化公司治理，并借助Bonney先生在行业内的深厚资历与领导力，推动公司未来发展。Michael W. Bonney在生物科技与制药行业拥有卓越的职业生涯和广泛认可，他的加入预计将为Immunic的战略方向与运营带来宝贵的指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184465464","title":"Immunic任命资深生物制药高管Michael A. Panzara博士担任首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1184465464","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184465464?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:32","pubTimestamp":1777372328,"startTime":"0","endTime":"0","summary":"生物医药公司Immunic, Inc.正式宣布，任命在生物制药领域拥有丰富经验的迈克尔·A·潘扎拉博士担任首席医疗官一职。潘扎拉博士在药物研发和临床开发方面具备深厚资历，此次任命将强化Immunic在创新疗法开发领域的领导团队。他的加入有望加速Immunic管线药物的临床推进，并为公司战略规划注入新的专业视角。这一人事变动彰显了Immunic持续加强研发实力、推进旗下候选药物全球开发的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135876008","title":"Immunic公司提交SEC文件：拟由售股股东注册转售最多4.582亿股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1135876008","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135876008?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:34","pubTimestamp":1775162054,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，生物制药公司Immunic, Inc.已启动一项股权转售计划。该计划允许售股股东注册并转售高达4.582亿股的普通股。\n此次股票注册旨在为现有股东提供流动性，同时扩大公司在资本市场的参与度。若全部股份完成转售，或将对企业股权结构产生一定影响。市场将密切关注后续进展，以评估其对股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151893813","title":"Immunic任命资深生物制药高管Jon Congleton，强化董事会阵容","url":"https://stock-news.laohu8.com/highlight/detail?id=1151893813","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151893813?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:32","pubTimestamp":1774953124,"startTime":"0","endTime":"0","summary":"生物制药公司Immunic, Inc.近日宣布，任命经验丰富的行业高管Jon Congleton加入其董事会。这一人事变动旨在借助Congleton在生物制药领域的深厚背景，进一步增强公司治理与战略决策能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612528477","title":"Immunic, Inc.盘中异动 临近收盘大幅下跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612528477","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612528477?lang=zh_cn&edition=full","pubTime":"2026-02-19 04:39","pubTimestamp":1771447178,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日04时39分，Immunic, Inc.股票出现波动，股价快速下挫5.15%。Immunic, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021904393897a677e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021904393897a677e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612463180","title":"Immunic, Inc.盘中异动 早盘股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612463180","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612463180?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:31","pubTimestamp":1771338661,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日22时31分，Immunic, Inc.股票出现波动，股价大幅上涨5.19%。截至发稿，该股报0.960美元/股，成交量139.356万股，换手率1.16%，振幅3.29%。Immunic, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021722310195415a50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021722310195415a50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162102677","title":"Immunic宣布超额认购至多4亿美元私募融资，加速向商业化阶段转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1162102677","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162102677?lang=zh_cn&edition=full","pubTime":"2026-02-13 19:47","pubTimestamp":1770983262,"startTime":"0","endTime":"0","summary":"2月13日——生物技术公司Immunic, Inc.宣布完成一笔超额认购的私募融资，规模最高可达4亿美元。此次融资所得将有力支持公司从专注于研发的企业向全面整合的商业化实体转型。\n与此同时，Immunic联合创始人兼首席执行官Daniel Vitt及董事会已启动新任首席执行官的遴选程序，标志着公司正积极为下一阶段的商业化运营储备领导力量。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143119752","title":"Immunic联合创始人兼CEO丹尼尔·维特与董事会将启动新CEO遴选程序","url":"https://stock-news.laohu8.com/highlight/detail?id=1143119752","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143119752?lang=zh_cn&edition=full","pubTime":"2026-02-13 19:33","pubTimestamp":1770982393,"startTime":"0","endTime":"0","summary":"生物制药公司Immunic, Inc.宣布，其联合创始人兼现任首席执行官丹尼尔·维特将与董事会共同启动新任首席执行官的遴选工作。这一决策标志着公司领导层即将进入战略过渡阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123995306","title":"Immunic公司融资收益将助推企业从研发导向转型为全整合商业实体","url":"https://stock-news.laohu8.com/highlight/detail?id=1123995306","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123995306?lang=zh_cn&edition=full","pubTime":"2026-02-13 19:32","pubTimestamp":1770982333,"startTime":"0","endTime":"0","summary":"Immunic公司（Immunic, Inc.）最新一轮融资所获资金，预计将有力支持公司实现战略转型——从以研发为核心业务的生物技术企业，升级为具备完整产业链能力的商业化实体。这一关键步骤标志着公司正积极拓展其商业运营能力，为未来产品市场化奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190675618","title":"Immunic宣布超额认购的私募融资，规模高达4亿美元，加速向商业化阶段转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1190675618","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190675618?lang=zh_cn&edition=full","pubTime":"2026-02-13 19:31","pubTimestamp":1770982273,"startTime":"0","endTime":"0","summary":"Immunic, Inc. (简称Immunic) 近日宣布了一项规模达4亿美元的私募融资计划，该计划已获得超额认购。此次融资旨在加速公司从研发阶段向商业化阶段的战略转型。通过这笔资金，Immunic将进一步提升其产品管线的商业化进程，加强市场布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609028483","title":"Immunic, Inc.盘中异动 急速跳水5.44%报0.620美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609028483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609028483?lang=zh_cn&edition=full","pubTime":"2026-02-05 00:13","pubTimestamp":1770221588,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日00时13分，Immunic, Inc.股票出现异动，股价快速下跌5.44%。截至发稿，该股报0.620美元/股，成交量29.409万股，换手率0.24%，振幅7.98%。Immunic, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020500130897a4e4b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020500130897a4e4b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162620335","title":"Immunic将在2026年Actrims论坛公布Vidofludimus Calcium二期Calliper试验新增数据，凸显其在进展型多发性硬化症领域的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1162620335","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162620335?lang=zh_cn&edition=full","pubTime":"2026-02-04 19:31","pubTimestamp":1770204680,"startTime":"0","endTime":"0","summary":"生物制药公司Immunic, Inc. 近日宣布，将于2026年举行的Actrims论坛上公布其候选药物Vidofludimus Calcium在二期Calliper临床试验中的补充数据。这一举措进一步彰显了该药物在治疗进展型多发性硬化症方面的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605423274","title":"Immunic, Inc.盘中异动 早盘大幅拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605423274","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605423274?lang=zh_cn&edition=full","pubTime":"2026-01-22 23:21","pubTimestamp":1769095264,"startTime":"0","endTime":"0","summary":"北京时间2026年01月22日23时21分，Immunic, Inc.股票出现波动，股价快速拉升5.07%。Immunic, Inc.股票所在的生物技术行业中，整体涨幅为1.04%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012223210497a2fbf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012223210497a2fbf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605297391","title":"Immunic, Inc.盘中异动 临近午盘大幅上涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605297391","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605297391?lang=zh_cn&edition=full","pubTime":"2026-01-21 00:34","pubTimestamp":1768926841,"startTime":"0","endTime":"0","summary":"北京时间2026年01月21日00时34分，Immunic, Inc.股票出现波动，股价快速上涨5.16%。截至发稿，该股报0.650美元/股，成交量103.103万股，换手率0.86%，振幅9.40%。Immunic, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121003401953d964e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121003401953d964e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518970204","title":"Immunic, Inc.盘中异动 下午盘大幅下挫5.22%报1.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518970204","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518970204?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:23","pubTimestamp":1741630982,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时23分，Immunic, Inc.股票出现波动，股价急速下挫5.22%。截至发稿，该股报1.09美元/股，成交量55.6483万股，换手率0.62%，振幅4.34%。Immunic, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311022302abf366de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311022302abf366de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516773256","title":"Immunic, Inc.盘中异动 股价大跌5.17%报1.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516773256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516773256?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:35","pubTimestamp":1741098950,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时35分，Immunic, Inc.股票出现异动，股价急速下挫5.17%。截至发稿，该股报1.10美元/股，成交量6.0825万股，换手率0.07%，振幅3.02%。Immunic, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223550963945e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223550963945e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IMUX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516267306","title":"Immunic, Inc.盘中异动 大幅拉升5.36%报1.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516267306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516267306?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:12","pubTimestamp":1740773541,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时12分，Immunic, Inc.股票出现波动，股价快速上涨5.36%。截至发稿，该股报1.18美元/股，成交量90.1006万股，换手率1.00%，振幅7.59%。Immunic, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301041221963460b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301041221963460b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514310833","title":"Immunic, Inc.盘中异动 下午盘股价大跌5.04%报1.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514310833","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514310833?lang=zh_cn&edition=full","pubTime":"2025-02-28 03:41","pubTimestamp":1740685278,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日03时41分，Immunic, Inc.股票出现异动，股价快速跳水5.04%。截至发稿，该股报1.11美元/股，成交量50.6064万股，换手率0.56%，振幅8.12%。Immunic, Inc.股票所在的生物技术行业中，整体跌幅为0.23%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228034118abdfb2d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228034118abdfb2d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514801536","title":"Immunic, Inc.股价飙升10.00% 市值跌390.15万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514801536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514801536?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:13","pubTimestamp":1740496417,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时13分，Immunic, Inc.股票出现波动，股价大幅上涨10.00%。截至发稿，该股报1.32美元/股，成交量18.1977万股，换手率0.20%，振幅3.09%。Immunic, Inc.股票所在的生物技术行业中，整体涨幅为0.80%。Immunic, Inc.公司简介：Immunic Inc 是一家临床阶段生物制药公司，正在开发一系列选择性口服免疫疗法，旨在治疗慢性炎症和自身免疫性疾病，包括溃疡性结肠炎，克罗恩病，复发性多发性硬化症和银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231337a2539192&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225231337a2539192&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IMUX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imux.com","stockEarnings":[{"period":"1week","weight":0.0223},{"period":"1month","weight":0.0778},{"period":"3month","weight":0.51},{"period":"6month","weight":1.4434},{"period":"1year","weight":0.8125},{"period":"ytd","weight":1.8293}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0},{"period":"3month","weight":0.0757},{"period":"6month","weight":0.0913},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Immunic, Inc.通过收购VitaGen公司的资产和业务，作为一个加利福尼亚州的公司于2003年5月23日开始运营，并于2003年6月更名为Vital Therapies, Inc.。2004年1月，公司再次在特拉华州注册成立。Immunic是一家专注于开发新型口服疗法以治疗神经系统疾病和胃肠道疾病的后期生物技术公司。公司总部位于纽约市，主要运营地点位于德国慕尼黑附近的格拉费尔芬。Immunic致力于推进小分子药物项目的临床开发，旨在满足患有严重慢性炎症和自身免疫性疾病患者的未满足医疗需求。这包括目前正处于III期临床开发阶段的vidofludimus钙项目（用于治疗复发型多发性硬化症患者），以及其他针对各种胃肠道疾病和自身免疫性疾病的项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.061205},{"month":2,"riseRate":0.416667,"avgChangeRate":0.061188},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.034042},{"month":4,"riseRate":0.25,"avgChangeRate":0.025838},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.041432},{"month":6,"riseRate":0.615385,"avgChangeRate":0.126262},{"month":7,"riseRate":0.538462,"avgChangeRate":0.048724},{"month":8,"riseRate":0.583333,"avgChangeRate":-0.042104},{"month":9,"riseRate":0.5,"avgChangeRate":-0.073457},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.035316},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001684},{"month":12,"riseRate":0.583333,"avgChangeRate":0.021046}],"exchange":"NASDAQ","name":"Immunic, Inc.","nameEN":"Immunic, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunic, Inc.(IMUX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Immunic, Inc.(IMUX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Immunic, Inc.,IMUX,Immunic, Inc.股票,Immunic, Inc.股票老虎,Immunic, Inc.股票老虎国际,Immunic, Inc.行情,Immunic, Inc.股票行情,Immunic, Inc.股价,Immunic, Inc.股市,Immunic, Inc.股票价格,Immunic, Inc.股票交易,Immunic, Inc.股票购买,Immunic, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunic, Inc.(IMUX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Immunic, Inc.(IMUX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}